Mega Genomics Limited (HKG:6667)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.00
0.00 (0.00%)
Jun 17, 2026, 3:59 PM HKT
Market Cap1.57B -31.9%
Revenue (ttm)275.03M +50.5%
Net Income30.07M -40.0%
EPS0.15 -37.0%
Shares Out 224.30M
PE Ratio45.97
Forward PEn/a
Dividend0.17 (2.48%)
Ex-Dividend DateMay 26, 2026
Volume24,400
Open6.00
Previous Close7.00
Day's Range5.00 - 7.01
52-Week Range5.00 - 7.53
Beta0.78
AnalystsStrong Buy
Price Target19.50 (+178.57%)
Earnings DateAug 28, 2026

About Mega Genomics

Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing; cardiovascular and cerebrovascul... [Read more]

Sector Healthcare
Founded 2016
Employees 206
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6667
Full Company Profile

Financial Performance

In 2025, Mega Genomics's revenue was 247.15 million, an increase of 50.49% compared to the previous year's 164.23 million. Earnings were 27.02 million, a decrease of -40.01%.

Financial numbers in CNY Financial Statements